The coronavirus pandemic has led to unprecedented acceleration in research and drug development, making it impossible to keep up with and sort through the high volume of clinical trials and scientific publications. Some patients with cancer may be at increased risk of severe complications or death due to COVID-19, and there is an urgent need to understand the implications of COVID-19 for patients with cancer.
Through the Reboot: COVID-Cancer Project, the tech nonprofit Reboot Rx has identified and aggregated published clinical studies and ongoing registered clinical trials relevant for patients with cancer and COVID-19. They have created a unified data resource that includes two datasets.
The datasets are available via free, interactive dashboards that can be accessed using the links below.
For additional information about this project and to download the full datasets, visit www.rebootrx.org/covid-cancer.
The first dataset draws from recent studies on COVID-19 in patients with cancer. This dataset includes published clinical studies that report on relevant outcomes from patients with cancer and COVID-19, as well as registered clinical trials specific to patients with cancer and COVID-19.
The current dataset includes more than 200 published clinical studies comprising more than twenty thousand patients with cancer and COVID-19 and over 150 relevant registered clinical trials. Extracted information includes study type, median age, gender ratio, tissue of origin and cancer type, and treatment-specific mortality.
The second dataset draws on years of cancer research on drugs that are now being tested for COVID-19. It contains information on the effects of investigational COVID-19 treatments on cancer (independent of COVID-19 infection).
This dataset includes published clinical studies that report on clinical outcomes related to the use of these treatments for cancer, as well as registered clinical trials investigating these treatments for cancer. From each study, detailed information such as cancer type, study type and clinical trial phase, whether the drug was used alone or in combination, and the therapeutic association was extracted.
Both Reboot: COVID-Cancer Project datasets are licensed by Reboot Rx, Inc. under CC BY-NC 4.0. If information from the project or datasets is utilized in published or unpublished work, please cite ‘Reboot: COVID-Cancer Project. Reboot Rx, Inc., 2020, https://rebootrx.org/covid-cancer. Accessed DATE’.
This is an ongoing effort and future data releases will include updates to the existing datasets, additional analyses, and communication of specific insights as they emerge. Contact the team at email@example.com to learn more or get involved.
Reboot Rx is the tech nonprofit dedicated to fast-tracking the development of affordable cancer treatments using repurposed generic drugs, AI technology, and innovative funding models. Learn more at www.rebootrx.org.
The information included in the Reboot: COVID-Cancer Project is for informational purposes only and is not intended to be used as medical advice, or as a substitute for the medical advice of a physician. Users assume full responsibility for use of the information and understand and agree that Reboot Rx, Inc. and its third party content providers are not responsible or liable for any claim, loss, or damage (including personal injury or wrongful death) resulting from its use. We disclaim any warranty concerning the accuracy, timeliness, and completeness of the information, and we are not responsible for the content of external sites.